Plasmapheresis plus LOLA in liver failure of children.
Not Applicable
Recruiting
- Conditions
- Health Condition 1: K720- Acute and subacute hepatic failure
- Registration Number
- CTRI/2023/02/049867
- Lead Sponsor
- Institute of Liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Pediatric Acute Liver Failure as defined by PALF-Study Group
2.5-18 years of age
3.INR > 2
4.Hepatic encephalopathy (defined by West Haven criteria)
5.Ammonia >100mcg/dL
Exclusion Criteria
1.Irreversible neurological injury
2.Previous treatment with LOLA within 48 hours before admission.
3.Acute kidney injury.
4.Acute on chronic liver failure
5.Those not giving consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of change in ammonia (baseline to day 3) in the 2 groupsTimepoint: 72 hrs
- Secondary Outcome Measures
Name Time Method Compare the adverse events in the 2 groupsTimepoint: 72 hours;Comparison of improvement in grade of encephalopathyTimepoint: Day 3 and day 7;Comparison of number of episodes of clinically raised intracranial pressure in the 2 groupsTimepoint: 72 hours;Comparison of ONSDTimepoint: 24,48 and 72 hours;Comparison of overall survivalTimepoint: Day 7 and Day 14;Comparison of plasma and dialysate glutamine levels after HVPETimepoint: 72 hours;Comparison of survival with native liver.Timepoint: Day 7 and Day 14;To compare the cumulative requirement of mannitol and propofol in the first 72 hoursTimepoint: 72 hr
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the ammonia-lowering effects of L-ornithine L-aspartate in pediatric acute liver failure?
How does the combination of plasmapheresis and LOLA compare to standard-of-care treatments for K720 hepatic failure in children?
Which biomarkers are associated with improved outcomes following therapeutic plasma exchange and LOLA in pediatric liver failure?
What are the potential adverse events of plasmapheresis plus LOLA in children with acute liver failure and how can they be managed?
Are there alternative compounds or combination therapies targeting ammonia metabolism in pediatric acute and subacute hepatic failure?